SLC5A2 and type 2 diabetes mellitus: In recent years, it has been shown in research studies that inhibitors of sodium-glucose cotransporter 2 (SGLT2i) are a new generation of oral hypoglycemic agents for patients with T2DM which acts by decreasing renal glucose reabsorption, thereby boosting urinary glucose excretion [7], thus lowering plasma glucose levels and contributing to a modest hemoglobin A1C (HbA1C) level [8].